Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS

Current Oncology

Volumn 19, Issue S1, 2012, Pages 33-44

  Vincent, Mark D ^a   Kuruvilla, M S ^a   Leighl, N B ^b   Kamel reid S ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

ALK; EGFR; KRAS; lung cancer; nsclc; prediction; prognosis

Indexed keywords

EID: 84907047245     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1149     Document Type: Article

References (95)

1. Cheng L, Alexander RE, Maclennan GT, et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 2012;25:347–69.
2. Pao W, Miller V, Zakowski M, et al. egf receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumours to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306–11.
3. Aung KL, Board RE, Ellison G, et al. Current status and future potential of somatic mutation testing from circulating free dna in patients with solid tumours. HUGO J 2010;4:11–21.
4. Goto K, Ichinose Y, Ohe Y, et al. Epidermal growth factor receptor mutation status in circulating free dna in serum: from ipass, a phase iii study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012;7:115–21.
5. Cohen S. Isolation of a mouse submaxillary gland protein ac-celerating incisor eruption and eyelid opening in the newborn animal. J Biol Chem 1962;237:1555–62.
6. Hollenberg MD, Cuatrecasas P. Epidermal growth factor: receptors in human fibroblasts and modulation of action by cholera toxin. Proc Natl Acad Sci U S A 1973;70:2964–8.
7. Burgess AW. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 2008;26:263–74.
8. Avraham R, Yarden Y. Feedback regulation of EGFR signal-ling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 2011;12:104–17.
9. Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cdna sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984;309:418–25.
10. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787–99.
11. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339–46.
12. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006;12:1647–53.
13. Bae NC, Chae MH, Lee MH, et al. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet 2007;173:107–13.
14. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163–7.
15. Takeuchi K, Ito F. egf receptor in relation to tumor de-velopment: molecular basis of responsiveness of cancer cells to egfr-targeting tyrosine kinase inhibitors. FEBS J 2010;277:316–26.
16. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–39.
17. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497–500.
18. Okamoto I. Epidermal growth factor receptor in relation to tumor development: egfr-targeted anticancer therapy. FEBS J 2010;277:309–15.
19. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase ii study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340–6.
20. Asahina H, Yamazaki K, Kinoshita I, et al. A phase ii trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95:998–1004.
21. Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid pcr clamp. Br J Cancer 2006;95:1483–9.
22. Yoshida K, Yatabe Y, Park JY, et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2007;2:22–8.
23. Sunaga N, Tomizawa Y, Yanagitani N, et al. Phase ii prospective study of the efficacy of gefitinib for the treatment of stage iii/iv non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 2007;56:383–9.
24. Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase ii trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (wjtog 0403). Br J Cancer 2008;98:907–14.
25. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442–9.
26. Sugio K, Uramoto H, Onitsuka T, et al. Prospective phase ii study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer 2009;64:314–18.
27. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958–67.
28. Lee JS, Park K, Kim SW, et al. A randomized phase iii study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung [abstract PRS.4]. J Thorac Oncol 2009;4(suppl 1):S283.
29. Ku GY, Haaland BA, de Lima Lopes G Jr. Gefitinib vs chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase iii trials. Lung Cancer 2011;74:469–73.
30. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–8.
31. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (wjtog 3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121–8.
32. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase iii, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (ipass). J Clin Oncol 2011;29:2866–74.
33. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation–positive non-small-cell lung cancer (optimal, ctong-0802): a multicenter, open-label, randomized, phase 3 study. Lancet Oncol 2011;12:735–42.
34. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation–positive non-small-cell lung cancer (erutac): a multicenter, open-label, randomized phase 3 trial. Lancet Oncol 2012;13:239–46.
35. Wu JY, Yu CJ, Shih JY, Yang CH, Yang PC. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. Lung Cancer 2010;67:348–54.
36. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as main-tenance treatment in advanced non-small-cell lung cancer: a multicentre, randomized, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521–9.
37. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in egfr kinase causes drug resistance by increasing the affinity for atp. Proc Natl Acad Sci U S A 2008;105:2070–5.
38. Sequist LV, Waltman BA, Dias–Santagata D, et al. Genotypic and histological evolution of lung cancer acquiring resistance to egfr inhibitors. Sci Transl Med 2011;3:75ra26.
39. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011;17:6298–303.
40. Becker A, Crombag L, Heideman DA, et al. Retreatment with erlotinib: regain of tki sensitivity following a drug holiday for patients with nsclc who initially responded to egfr-tki treatment. Eur J Cancer 2011;47:2603–6.
41. Oxnard GR, Janjigian YY, Arcila ME, et al. Maintained sensitivity to egfr tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. Clin Cancer Res 2011;17:6322–8.
42. Park S, Holmes–Tisch AJ, Cho EY, et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 2009;4:809–15.
43. Hirsch FR, Varella–Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase iii placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034–42.
44. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study br.21. J Clin Oncol 2008;26:4268–75.
45. Schneider CP, Heigener D, Schott-von-Römer K, et al. Epidermal growth factor receptor–related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the trust study. J Thorac Oncol 2008;3:1446–53.
46. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527–37.
47. Hirsch FR, Varella–Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase iii placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034–42.
48. Ellis PM, Blais N, Soulieres D, et al. A systematic review and Canadian consensus recommendations on the use of biomark-ers in the treatment of non-small cell lung cancer. J Thorac Oncol 2011;6:1379–91.
49. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (flex): an open-label randomised phase iii trial. Lancet 2009;373:1525–31.
50. Pirker R, Pereira JR, von Pawel J, et al. Epidermal growth factor receptor (EGFR) expression as a predictor for survival of first line chemotherapy plus cetuximab in flex study patients with advanced non-small cell lung cancer (nsclc). Lancet Oncol 2012;13:33–42.
51. Pirker R, Herth FJ, Kerr KM, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010;5:1706–13.
52. Yu J, Kane S, Wu J, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009;15:3023–8.
53. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010;12:169–76.
54. Kawahara A, Yamamoto C, Nakashima K, et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohisto-chemical analysis. Clin Cancer Res 2010;16:3163–70.
55. Kato Y, Peled N, Wynes MW, et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010;5:1551–8.
56. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366–77.
57. Sequist LV, Nagrath S, Toner M, Haber DA, Lynch TJ. The ctc-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol 2009;4:281–3.
58. Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital pcr in non-small cell lung cancer patients. Clin Cancer Res 2009;15:2076–84.
59. Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma dna samples predict tumor response in Chinese patients with stages iiib to iv non-small-cell lung cancer. J Clin Oncol 2009;27:2653–9.
60. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 1994;263:1281–4.
61. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561–6.
62. Inamura K, Takeuchi K, Togashi Y, et al. EML4–ALK lung cancers are characterized by rare other mutations, a ttf-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009;22:508–15.
63. Shaw AT, Yeap BY, Mino–Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbour EML4–ALK. J Clin Oncol 2009;27:4247–53.
64. Subramanian J, Corrales L, Soulieres D, Morgensztern D, Govindan R. Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) focus on tumor biology and biomarkers related to lung cancer. J Thorac Oncol 2011;6:399–403.
65. Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther 2011;5:471–85.
66. Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase i dose escalation trial of an oral c-Met and Alk inhibitor, PF-02341066 [abstract 3509]. J Clin Oncol 2009;27:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID= 65&abstractID=30947; cited May 23, 2012]
67. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693–703.
68. Crino L, Kim DW, Riely GJ, et al. Initial phase ii results with crizotinib in advanced ALK-positive non-small cell lung cancer (nsclc): profile 1005 [abstract 7514]. J Clin Oncol 2011;29:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID= 102&abstractID=81844; cited May 23, 2012]
69. Yang P, Kulig K, Boland JM, et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol 2012;7:90–7.
70. Choi YL, Soda M, Yamashita Y, et al. EML4–ALK mutations in lung cancer that confer resistance to Alk inhibitors. N Engl J Med 2010;363:1734–9.
71. Katayama R, Khan TM, Benes C, et al. Therapeutic strate-gies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4–ALK. Proc Natl Acad Sci U S A 2011;108:7535–40.
72. Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective Alk inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011;19:679–90.
73. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863–70.
74. Camidge DR, Kono SA, Lu X, et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011;6:774–80.
75. Takeda M, Okamoto I, Sakai K, et al. Successful long-term treatment with pemetrexed of nsclc associated with EML4– ALK and low thymidylate synthase expression. Clin Lung Cancer 2012;13:157–9.
76. Lee JO, Kim TM, Lee SH, et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 2011;6:1474–80.
77. Chang EH, Gonda MA, Ellis RW, Scolnick EM, Lowy DR. Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc Natl Acad Sci U S A 1982;79:4848–52.
78. Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 2011;223:219–29.
79. Xu N, Lao Y, Zhang Y, Gillespie DA. Akt: a double-edged sword in cell proliferation and genome stability. J Oncol 2012;2012:951724.
80. Forbes S, Clements J, Dawson E, et al. cosmic 2005. Br J Cancer 2006;94:318–22.
81. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and dis-tinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731–4.
82. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012;104:228–39.
83. Luo J, Emanuele MJ, Li D, et al. A genome-wide rnai screen identifies multiple synthetic lethal interactions with the ras oncogene. Cell 2009;137:835–48.
84. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900–9.
85. Brugger W, Triller N, Blasinska–Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib mainte-nance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:4113–20.
86. O’Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular bio-markers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 flex study. Lancet Oncol 2011;12:795–805.
87. Bacus S. KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non-small cell lung cancer [abstract PR-2]. Mol Cancer Ther 2011;10 (suppl 1):.
88. Feng Y, Thiagarajan PS, Ma PC. Met signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 2012;7:459–67.
89. Ma PC, Tretiakova MS, MacKinnon AC, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008;47:1025–37.
90. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ErbB3 signaling. Science 2007;316:1039–43.
91. Cappuzzo F, Jänne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009;20:298–304.
92. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932–7.
93. Ou SH, Kwak EL, Siwak–Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal–epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6:942–6.
94. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29:4803–10.
95. Chi A, Kwak EL, Clark JW, et al. Clinical improvement and rapid radiographic regression induced by a Met inhibitor in a patient with MET-amplified glioblastoma [abstract 2072]. J Clin Oncol 2011;29:. [Available online at: http://www.asco. org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_vi ew&confID=102&abstractID=82407; cited May 23, 2012]